Reunion Neuroscience (TSX:REUN) Days Payable : 0.00 (As of Mar. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Reunion Neuroscience Days Payable?

Reunion Neuroscience's average Accounts Payable for the three months ended in Mar. 2023 was C$0.00 Mil. Reunion Neuroscience's Cost of Goods Sold for the three months ended in Mar. 2023 was C$0.00 Mil.

The historical rank and industry rank for Reunion Neuroscience's Days Payable or its related term are showing as below:

TSX:REUN's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 147.17
* Ranked among companies with meaningful Days Payable only.

Reunion Neuroscience's Days Payable stayed the same from Mar. 2022 (0.00) to Mar. 2023 (0.00). stayed the same

Reunion Neuroscience Days Payable Historical Data

The historical data trend for Reunion Neuroscience's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reunion Neuroscience Days Payable Chart

Reunion Neuroscience Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Days Payable

10,950.00

48.10

Reunion Neuroscience Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Days Payable	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Reunion Neuroscience's Days Payable

For the Biotechnology subindustry, Reunion Neuroscience's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reunion Neuroscience's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reunion Neuroscience's Days Payable distribution charts can be found below:

* The bar in red indicates where Reunion Neuroscience's Days Payable falls into.

Reunion Neuroscience Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Reunion Neuroscience's Days Payable for the fiscal year that ended in Mar. 2023 is calculated as

	Days Payable (A: Mar. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Mar. 2022 )	+	Accounts Payable (A: Mar. 2023 ))	/	count )	/	Cost of Goods Sold (A: Mar. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Reunion Neuroscience's Days Payable for the quarter that ended in Mar. 2023 is calculated as:

	Days Payable (Q: Mar. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2022 )	+	Accounts Payable (Q: Mar. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Reunion Neuroscience Days Payable Related Terms

Thank you for viewing the detailed overview of Reunion Neuroscience's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Reunion Neuroscience (TSX:REUN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reunion Neuroscience Inc (TSX:REUN) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Duncan Street, Lower North Suite, Toronto, ON, CAN, M5V 2C3

Website

https://www.reunionneuro.com

Reunion Neuroscience Inc is engaged in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company's asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.